1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1640
  5. Art Unit 1646
  6. Examiner Gustilo

Examiner Gustilo Estella M

1646-GUSTILO-ESTELLA-M

Employment Information

Art Unit:1646 — Drug, bio-affecting and body treating compositions
Group:1640 — Immunology including antibodies, B&T lymphocytes, antigen presenting cells and Gram-positive/Negative Bacteria, Parasitic and Fungal Immunology
Classes: 424 — Drug, bio-affecting and body treating compositions
530 — Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
435 — Chemistry: molecular biology and microbiology
514 — Drug, bio-affecting and body treating compositions
Phone:(703) 756-1706
Email:None
Location:None
Title:Pat Examnr (Biolgy)
Service:3 years
Grade:GS-11

Grant Rate and Difficulty Ranking

3-Year Grant rate: 17% over 6 cases
Difficulty: Not enough data to rank
Difficulty Percentile:

With Examiner Gustilo, you have a 17% chance of getting an issued patent by 3 years after the first office action.

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Gustilo, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1646

Examiner Gustilo's grant rate is lower than that of Art Unit 1646 and lower than that of the USPTO.

Average Office Actions Per Grant
Examiner Gustilo 1.3
Art Unit 1646 1.5

Interview Benefit

Grant Rate without Interview

Examiner Gustilo has granted 1 of 5 cases without any applicant-requested interviews for a grant rate of 20%.

Grant Rate with Interview

Examiner Gustilo has granted 0 of 1 cases with at least one applicant-requested interview for a grant rate of 0%.

Interview Benefit

With Examiner Gustilo, conducting an interview decreases your chance of getting a patent granted by 100%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
18999104 Trem2 Stabilizing Antibodies Rejection information available with a Premium Stats subscription. See our pricing. Patented View
18897951 Bispecific Antibodies Targeting Pd1 And Vegf Patented View
18064081 Dosing Of Polyomavirus Neutralizing Antibodies Abandoned View
17258245 Co-Receptor Systems For Treating Infectious Diseases Abandoned View
17441706 Antigen-Binding Agents That Specifically Bind Epidermal Growth Factor Receptor Variant Iii Patented View
18290171 Anti-Tigit Antibodies And Use Thereof Patented View
17612954 Antibodies That Bind Human Metapneumovirus Fusion Protein And Their Use Patented View
17613122 Cra4s1 Gene, Encoded Cra4s1 Protein, And Application Patented View
19035354 Anti-Transferrin Receptor Antibodies, Conjugates Thereof, And Uses Thereof Patented View
17436934 T Cell Receptors And Methods Of Use Thereof Patented View
17311767 Dimerizing Agent Regulated Immunoreceptor Complexes Abandoned View
17871397 Antineoplastic Combinations With M-Tor Inhibitor, Trastuzumab And/or Hki-272 Abandoned View
17416829 Novel Cytokines And Use Thereof Patented View
16969056 Cd83-Binding Chimeric Antigen Receptors Patented View
18065472 Anti-Tau Antibodies And Methods Of Use Patented View
17177052 Cryopreserved Nk Cells Preloaded With An Antibody Construct Abandoned View
18014457 Antibodies That Bind Psma And Gamma-Delta T Cell Receptors Abandoned View
17424691 Immunoglobulin Purification Method And Immunoglobulin Purification Device, And Immunoglobulin Production Method And Immunoglobulin Production Device Abandoned View
18919082 Compositions For Treating Cancer Patented View
17418906 Pathogen Binding Proteins Patented View
18656081 Antibodies That Bind Psma And Gamma-Delta T Cell Receptors Patented View
17251397 Methods And Compositions For Chimeric Antigen Receptor Targeting Cancer Cells Patented View
18058167 Methods For Preventing, Reversing Or Treating An Infection Induced By A Virus That Enters Host Cells Via Ace2 Receptor Abandoned View
18746792 Lag-3 Combination Therapy For The Treatment Of Cancer Abandoned View
17548340 Antineoplastic Combinations With M-Tor Inhibitor, Trastuzumab And/or Hki-272 Abandoned View
18660672 Antibodies Capable Of Binding To Ox40, Variants Thereof And Uses Thereof Patented View
18018536 Anti-Variable Muc1* Antibodies And Uses Thereof Abandoned View
17434286 Therapeutic Antigen Binding Proteins Specific For Cd93 And Methods Of Use Thereof Patented View
17350995 Antibodies Specific To Muc18 Patented View
17422186 Anti-B7s1 Polypeptides And Their Use Patented View
17297821 Compositions And Methods For The Treatment And/or Prevention Of Her2+ Cancers Abandoned View
17993654 Methods For Treating Cancer With Bispecific Anti-Cd3 X Muc16 Antibodies And Anti-Ctla-4 Antibodies Abandoned View
16972895 Set Of Reagents For Detecting A Marker Of Epithelial Carcinomas Abandoned View
17415993 Clazakizumab In The Treatment Of Chronic Antibody-Mediated Rejection Of Organ Transplant Abandoned View
17267115 Anti-Il-1beta Antibody And Pharmaceutical Composition Thereof And Use Of Same Patented View
17420537 Methods And Pharmaceutical Compositions For Enhancing Cd8+ T Cell-Dependent Immune Responses In Subjects Suffering From Cancer Abandoned View
17306913 14-3-3 Eta Antibodies And Uses Thereof For The Diagnosis And Treatment Of Arthritis Patented View
17287164 Methods And Materials For Treating Cancer Patented View
17380483 Pharmaceutical Composition Comprising Antibody, Device Comprising Same, And Use Thereof Abandoned View
17421770 Pharmaceutical Composition Comprising Antibody, Device Comprising Same, And Use Thereof Abandoned View
17380445 Pharmaceutical Composition Comprising Antibody, Device Comprising Same, And Use Thereof Abandoned View
17428650 Methods And Compositions For Treating Cancer Abandoned View
16291207 Treatment Of Type 1 Diabetes And Other Conditions Using The Gut Microbiome Abandoned View
17048748 T Cell Receptors With Mage-B2 Specificity And Uses Thereof Patented View
16651531 Method For Depleting Cytotoxic T Cells Using An Anti-Lag-3 Antibody Composition Patented View
16999823 Methods For Scar Prevention Abandoned View
17551006 S309 Chimeric Antigen Receptors And Methods Of Use Patented View
17283490 Reversal Agents For Neutralizing The Therapeutic Activity Of Anti-Fxia Antibodies Abandoned View
17291674 Anti-Cd73 Antibody, Antigen-Binding Fragment Thereof And Application Thereof Abandoned View
17259754 Fc Binding Fragments Comprising A Cd137 Antigen-Binding Site Patented View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.